查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症单克隆抗体市场规模、份额和趋势分析报告：按类型（嵌合抗体、人源化抗体）、按应用（血癌、乳腺癌、肺癌）、按最终用户、按地区、按细分市场，2022-2030
市场调查报告书
商品编码
1114173

癌症单克隆抗体市场规模、份额和趋势分析报告：按类型（嵌合抗体、人源化抗体）、按应用（血癌、乳腺癌、肺癌）、按最终用户、按地区、按细分市场，2022-2030

Cancer Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Chimeric Antibodies, Humanized Antibodies), By Application (Blood Cancer, Breast Cancer, Lung Cancer), By End-user, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

癌症单克隆抗体市场的增长和趋势

Grandview Research 的一份新报告显示，到 2030 年，全球癌症单克隆抗体市场预计将达到 1597 亿美元。

从 2022 年到 2030 年，市场预计将以 11.2% 的复合年增长率增长。癌症患病率上升、产品批准以及强大的管道是推动市场增长的主要因素。此外，预计该领域研发资金的增加将影响该行业的增长。此外，蓬勃发展的生物仿製药市场预计将在预测期内提供更多有利可图的机会。

非小细胞肺癌 (NSCLC) 是一种常见的肺癌类型。只有约 8% 的转移性 NSCLC 患者在确诊后存活 5 年或更长时间，大多数情况下预后较差。此外，目前还没有针对 HER2 的治疗药物被批准用于治疗 HER2 突变的非小细胞肺癌，大约 2-4% 的非鳞状非小细胞肺癌患者存在这种情况。然而，过去两年取得了进展，主要是在一线治疗方面，但仍有大量未满足的医疗需求。例如，2022 年 4 月，第一三共和阿斯利康在美国接受了 Enhertu 的生物製品许可补充申请（sBLA），用于治疗成人不可切除的 NSCLC。

过去三年来，单克隆抗体的开发在临床和技术上都取得了长足的进步。由于其安全性、特异性和有效性等优点，现已被广泛接受为先进的治疗药物。尤其是癌症，是最重要的药物应用，占单克隆抗体相关研发项目的近 50%。

2021 年 6 月，欧盟委员会批准百时美施贵宝的 Yervoy 和 Opdivo 联合用于治疗恶性胸膜间皮瘤患者。同样在 2022 年 6 月，再生元宣布计划购买赛诺菲在赛诺菲-再生元合作伙伴 Ribtayo 中的股份，从而赋予该公司对该药物的独家全球开发、製造和商业化权利。此外，2020 年 5 月，吉利德科学和 Arrcus Biosciences 建立了为期 10 年的合作伙伴关係，共同商业化和共同开发 Arrcus 管道中当前和未来的治疗候选药物。 Arkas 目前对其范围内的分子进行了 10 项临床试验，其中包括 3 种单克隆抗体。

随着 COVID-19 在 2020 年 3 月的最后两週在美国和欧洲达到临界点，在各行各业都观察到了其深远的影响，医院推迟或取消了癌症治疗。并停止了临床试验.这在一定程度上阻碍了市场的增长。然而，随着治疗程序的恢復，製造商观察到 2021 年下半年的业务稳步改善。

癌症单克隆抗体市场报告要点。

按产品类型，由于小鼠单克隆抗体的低成本、可用性和快速生产时间等因素，2021 年人类细分市场将占据很大份额。然而，由于产品批准和产品发布的数量不断增加，预计人形机器人细分市场将在预测期内保持最高的复合年增长率

由于血液系统疾病的患病率不断增加以及强大的管道，血液系统癌症应用部门在 2021 年占据了可观的收入份额。此外，肺癌部分预计在预测期内以最高复合年增长率增长

2021 年，由于患者入院人数激增，医院部分成为主要的最终用户部分。此外，设施内创新药物疗法的可用性正在推动患者的偏好

由于主要市场参与者的战略行动、不断上升的癌症病例以及该地区政府的支持举措，2021 年全球市场由北美主导

在亚太地区，由于国际和国家合作的增加，尤其是发达国家和发展中国家实体之间的合作，预计未来市场将显着增长

内容

第一章研究方法

  • 信息采购
  • 数据分析

第 2 章执行摘要

  • 市场概况

第 3 章癌症单克隆抗体市场变量、趋势和范围

  • 市场系列展望
    • 母公司市场展望
    • 辅助市场展望
  • 绘製渗透率和增长前景
  • 市场细分和范围
  • 癌症单克隆抗体市场分析市场动态
  • 市场驱动因素分析
    • 癌症患病率增加
    • 加大研发投入
    • 对个性化医疗的偏好不断上升
  • 市场约束分析
    • 单克隆抗体治疗成本高
  • 主要机会
    • 蓬勃发展的生物仿製药市场
  • 癌症单克隆抗体市场 PESTLE 分析
  • 行业分析 - 搬运工
  • 分析重大交易和战略联盟
    • 合资企业
    • 併购
    • 许可和合作伙伴关係
    • 技术合作
    • 战略撤资
  • COVID-19 影响分析

第 4 章癌症单克隆抗体市场：按类型分列的细分分析，2018-2030 年（十亿美元）

  • 癌症单克隆抗体市场：类型变异分析
  • 人性化
  • 人类
  • 嵌合体
  • 老鼠

第 5 章癌症单克隆抗体市场：细分分析，按应用，2018-2030 年（十亿美元）

  • 癌症单克隆抗体市场：应用变化分析
  • 血癌
  • 乳腺癌
  • 肺癌
  • 黑色素瘤
  • 结肠癌
  • 肝癌
  • 其他

第 6 章癌症单克隆抗体市场：细分分析，按最终用户，2018-2030 年（十亿美元）

  • 癌症单克隆抗体市场：最终用户波动分析
  • 医院
  • 调查
  • 其他

第 7 章癌症单克隆抗体市场：细分分析，按地区，2018-2030 年（十亿美元）

  • 癌症单克隆抗体市场：区域差异分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
  • 亚太地区
    • 日本
    • 中国
    • 印度
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • 中东和非洲 (MEA)
    • 南非
    • 沙特阿拉伯

第 8 章竞争格局

  • 供应商格局
    • 全球癌症单克隆抗体市场：2021 年主要参与者的市场份额分析
  • 公司简介
    • F. HOFFMANN-LA ROCHE LTD
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • 百时美施贵宝公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • 默克公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • 葛兰素史克公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • 强生&强生
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • AMGEN, INC.
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • 诺华公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • 阿斯利康公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • 礼来公司
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
    • ABB VIE
      • 公司简介
      • 财务表现
      • 产品基准
      • 管道分析
      • 战略举措
Product Code: GVR-4-68039-957-1

Cancer Monoclonal Antibodies Market Growth & Trends:

The global cancer monoclonal antibodies market size is expected to reach USD 159.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.2% from 2022 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.

Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.

The development of monoclonal antibodies has been great both in clinical and technical research applications over the past three years. Given their advantages of safety, specificity, and efficacy, there is now prevalent acceptance of mAbs as advanced therapeutic agents. Cancer is the most dominating and important area of medicinal application, accounting for almost 50% of all monoclonal antibodies-related R&D programs.

In addition, in June 2021, the European Commission approved Bristol Myers Squibb's combination therapy of Yervoy and OPDIVO to treat patients for malignant pleural mesothelioma. In June 2022, Regeneron Pharmaceuticals, Inc. announced its plan to purchase Sanofi's stake in the Sanofi and Regeneron partnership on Libtayo, providing the company with exclusive global development, manufacturing, and commercialization rights to the medicine. Furthermore, in May 2020, Gilead Sciences, Inc. and Arcus Biosciences, Inc. entered into a 10-year partnership to co-commercialize and co-develop recent and future therapeutic candidates in Arcus's pipeline. Arcus has 10 current clinical studies of molecules in its range with three monoclonal antibodies.

As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials. This has hampered the market growth to an extent. However, as treatment procedures resumed, manufacturers observed a steady improvement in business in the second half of 2021.

Cancer Monoclonal Antibodies Market Report Highlights:

  • By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
  • The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
  • In 2021, the hospital segment was the leading end-user segment due to an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in the facility drives the patient preference
  • North America dominated the global market in 2021, due to the strategic activities of key market players, increasing cancer cases, and supportive government efforts in this region
  • In Asia Pacific, the market is expected to grow considerably in the future due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Data Analysis

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Cancer Monoclonal Antibodies Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
    • 3.1.2 Ancillary market outlook
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Market Segmentation & Scope
  • 3.4 Cancer Monoclonal Antibodies Market Analysis Market Dynamics
  • 3.5 Market Driver Analysis
    • 3.5.1 Growing prevalance of cancer
    • 3.5.2 Increasing investement in research and development
    • 3.5.3 Rising preference for personalized medicines
  • 3.6 Market Restraint Analysis
    • 3.6.1 High cost of monoclonal antiobdy therpaeutics
  • 3.7 Key Opportunities
    • 3.7.1 Booming Biosimilar market
  • 3.8 Cancer Monoclonal Antibodies Market - PESTLE analysis
  • 3.9 Industry Analysis - Porter's
  • 3.10 Major Deals & Strategic Alliances Analysis
    • 3.10.1 Joint ventures
    • 3.10.2 Mergers & acquisitions
    • 3.10.3 Licensing & partnership
    • 3.10.4 Technology collaborations
    • 3.10.5 Strategic divestments
  • 3.11 COVID-19 Impact Analysis

Chapter 4 Cancer Monoclonal Antibodies Market: Segment Analysis, by Type, 2018 - 2030 (USD Billion)

  • 4.1 Cancer Monoclonal Antibodies Market: Type Movement Analysis
  • 4.2 Humanized
    • 4.2.1 Humanized Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.3 Human
    • 4.3.1 Human Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.4 Chimeric
    • 4.4.1 Chimeric Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 4.5 Murine
    • 4.5.1 Murine Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 5 Cancer Monoclonal Antibodies Market: Segment Analysis, By Application, 2018 - 2030 (USD Billion)

  • 5.1 Cancer Monoclonal Antibodies Market: Application Movement Analysis
  • 5.2 Blood Cancer
    • 5.2.1 Blood Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.3 Breast Cancer
    • 5.3.1 Breast Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.4 Lung Cancer
    • 5.4.1 Lung Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.5 Melanoma
    • 5.5.1 Melanoma Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.6 Colorectal Cancer
    • 5.6.1 Colorectal Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.7 Liver Cancer
    • 5.7.1 Liver Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 5.8 Others
    • 5.8.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 6 Cancer Monoclonal Antibodies Market: Segment Analysis, By End-User, 2018 - 2030 (USD Billion)

  • 6.1 Cancer Monoclonal Antibodies Market: End-User Movement Analysis
  • 6.2 Hospitals
    • 6.2.1 Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.3 Research Institutes
    • 6.3.1 Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 6.4 Others
    • 6.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Billion)

Chapter 7 Cancer Monoclonal Antibodies Market: Segment Analysis, By Region, 2018 - 2030 (USD Billion)

  • 7.1 Cancer Monoclonal Antibodies Market: Regional Movement Analysis
  • 7.2 North America
    • 7.2.1 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.2.3 Canada
      • 7.2.3.1 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.3 Europe
    • 7.3.1 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.2 U.K.
      • 7.3.2.1 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.3 Germany
      • 7.3.3.1 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.3.4 France
      • 7.3.4.1 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.2 Japan
      • 7.4.2.1 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.3 China
      • 7.4.3.1 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.4.4 India
      • 7.4.4.1 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.5 Latin America
    • 7.5.1 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • 7.6 Middle East and Africa (MEA)
    • 7.6.1 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)

Chapter 8 Competitive Landscape

  • 8.1 Vendor Landscape
    • 8.1.1 Global Cancer Monoclonal Antibody Market: Key Company Market Share Analysis, 2021
  • 8.2 Company Profiles
    • 8.2.1 F. HOFFMANN-LA ROCHE LTD
      • 8.2.1.1 Company overview
      • 8.2.1.2 Financial performance
      • 8.2.1.3 Product benchmarking
      • 8.2.1.4 Pipeline analysis
      • 8.2.1.5 Strategic initiatives
    • 8.2.2 BRISTOL MYERS SQUIBB CO.
      • 8.2.2.1 Company overview
      • 8.2.2.2 Financial performance
      • 8.2.2.3 Product benchmarking
      • 8.2.2.4 Pipeline analysis
      • 8.2.2.5 Strategic initiatives
    • 8.2.3 MERCK & CO.
      • 8.2.3.1 Company overview
      • 8.2.3.2 Financial performance
      • 8.2.3.3 Product benchmarking
      • 8.2.3.4 Pipeline analysis
      • 8.2.3.5 Strategic initiatives
    • 8.2.4 GLAXOSMITHKLINE PLC
      • 8.2.4.1 Company overview
      • 8.2.4.2 Financial performance
      • 8.2.4.3 Product benchmarking
      • 8.2.4.4 Pipeline analysis
      • 8.2.4.5 Strategic initiatives
    • 8.2.5 JOHNSON & JOHNSON
      • 8.2.5.1 Company overview
      • 8.2.5.2 Financial performance
      • 8.2.5.3 Product benchmarking
      • 8.2.5.4 Pipeline analysis
      • 8.2.5.5 Strategic initiatives
    • 8.2.6 AMGEN, INC.
      • 8.2.6.1 Company overview
      • 8.2.6.2 Financial performance
      • 8.2.6.3 Product benchmarking
      • 8.2.6.4 Pipeline analysis
      • 8.2.6.5 Strategic initiatives
    • 8.2.7 NOVARTIS AG
      • 8.2.7.1 Company overview
      • 8.2.7.2 Financial performance
      • 8.2.7.3 Product benchmarking
      • 8.2.7.4 Pipeline analysis
      • 8.2.7.5 Strategic initiatives
    • 8.2.8 ASTRAZENECA PLC
      • 8.2.8.1 Company overview
      • 8.2.8.2 Financial performance
      • 8.2.8.3 Product benchmarking
      • 8.2.8.4 Pipeline analysis
      • 8.2.8.5 Strategic initiatives
    • 8.2.9 ELI LILLY AND COMPANY
      • 8.2.9.1 Company overview
      • 8.2.9.2 Financial performance
      • 8.2.9.3 Product benchmarking
      • 8.2.9.4 Pipeline analysis
      • 8.2.9.5 Strategic initiatives
    • 8.2.10 ABBVIE
      • 8.2.10.1 Company overview
      • 8.2.10.2 Financial performance
      • 8.2.10.3 Product benchmarking
      • 8.2.10.4 Pipeline analysis
      • 8.2.10.5 Strategic initiatives

List of Tables

  • TABLE 1 Cancer monoclonal antibodies market - Industry snapshot & key buying criteria
  • TABLE 2 Cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 3 Cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 4 Cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 5 Cancer monoclonal antibodies market, by region, 2018 - 2030 (USD Billion)
  • TABLE 6 North America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 7 North America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 8 North America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 9 U.S. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 10 U.S. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 11 U.S. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 12 Canada cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 13 Canada cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 14 Canada cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 15 Europe cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 16 Europe cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 17 Europe cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 18 U.K. cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 19 U.K. cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 20 U.K. cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 21 Germany cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 22 Germany cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 23 Germany cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 24 France cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 25 France cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 26 France cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 27 Asia Pacific cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 28 Asia Pacific cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 29 Asia Pacific cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 30 Japan cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 31 Japan cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 32 Japan cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 33 China cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 34 China cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 35 China cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 36 India cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 37 India cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 38 India cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 39 Latin America cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 40 Latin America cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 41 Latin America cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 42 Brazil cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 43 Brazil cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 44 Brazil cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 45 Mexico cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 46 Mexico cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 47 Mexico cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 48 MEA cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 49 MEA cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 50 MEA cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 51 South Africa cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 52 South Africa cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 53 South Africa cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)
  • TABLE 54 Saudi Arabia cancer monoclonal antibodies market, by type, 2018 - 2030 (USD Billion)
  • TABLE 55 South Abrabia cancer monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
  • TABLE 56 South Abrabia cancer monoclonal antibodies market, by end-user, 2018 - 2030 (USD Billion)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain Based Sizing & Forecasting
  • FIG. 6 QFD Modelling For Market Share Assessment
  • FIG. 7 Market summary 2022 (USD Billion)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Cancer monoclonal antibodies market analysis, 2018 - 2030 (USD Billion)
  • FIG. 11 Cancer monoclonal antibodies market dynamics
  • FIG. 12 Market driver relevance analysis (Current & future impact)
  • FIG. 13 Global pharmaceutical industry, 2014 - 2022 (USD Billion)
  • FIG. 14 Market restraint relevance analysis (Current & future impact)
  • FIG. 15 Key Opportunities
  • FIG. 16 Cancer monoclonal antibodies market PESTEL analysis
  • FIG. 17 Porter's Five Forces Analysis
  • FIG. 18 Cancer monoclonal antibodies market, type outlook key takeaways (USD Billion)
  • FIG. 19 Cancer monoclonal antibodies market: Type movement analysis (USD Billion)
  • FIG. 20 Humanized market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 21 Human market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 20 Chimeric market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 21 Murine market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 22 Cancer monoclonal antibodies market, application outlook key takeaways (USD Billion)
  • FIG. 23 Cancer M monoclonal antibodies market: Therapeutic application movement analysis (USD Billion)
  • FIG. 24 Blood cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 25 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 26 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 27 Melanoma market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 28 Colorectal cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 29 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 30 Other applications market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 31 Cancer monoclonal antibodies market, end-user outlook key takeaways (USD Billion)
  • FIG. 32 Cancer monoclonal antibodies market: End-user movement analysis (USD Billion)
  • FIG. 33 Hospitals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 34 Research Institutes market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 35 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • FIG. 36 Regional market place: Key takeaways (USD Billion)
  • FIG. 37 Cancer monoclonal antibodies market: Regional movement analysis (USD Billion)
  • FIG. 38 North America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 39 U.S. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 40 Canada cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 41 Europe cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 42 U.K. cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 43 Germany cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 44 France cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 45 Asia Pacific cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 46 Japan cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 47 China cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 48 India cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 49 Latin America cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 50 Brazil cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 51 Mexico cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 52 MEA cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 53 South Africa cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
  • FIG. 54 Saudi Arabia cancer monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Billion)